Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL

Jiyi Fu, Boyue Zheng, Jun Wang, Jiafei Wu, Hong Zheng, Xiaobing Huang, Xi Yang, Li Hui

Blood (2025) 146 (Supplement 1): 1579.

https://doi.org/10.1182/blood-2025-1579

Published: 2025

Journal Articles

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

XI Yang, Haadi Ali, Dana Bossert, Carla Isabel Borre, Brinda H Shukla, Jacquelyn Fitzgerald, Mikaela McDonough, Corbin Wright, Fnu Amisha, Samuel Reynolds, Eric Jacobsen, Eli Diamond, Gaurav Goyal, Jithma Abeykoon, Ronald Go, Asra Ahmed

Blood (2025) 146 (Supplement 1): 726.

https://doi.org/10.1182/blood-2025-726

Published: 2025

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma

XI Yang, Weiwei Zhang, Anamarija Perry, Pinyu Hou, Winston Lee, James Godfrey, Yasmin Karimi, Joo Song

Blood (2025) 146 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2025-3542

Published: 2025

Journal Articles

Real-world efficacy and prognostic modeling of venetoclax-enhanced intensive chemotherapy in fit AML

Boyue Zheng, Jiyi Fu, Jiafei Wu, Xiaobing Huang, Hong Zheng, Xi Yang, Li Hui

Blood (2025) 146 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2025-6985

Published: 2025

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia post allogeneic hematopoietic stem cell transplantation.

Xi Yang, cheng Li, Yu Wang, Hong Zheng, Xuemei Ye, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 7808.

https://doi.org/10.1182/blood-2025-7808

Published: 2025

Journal Articles

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

Xi Yang, chenglong Li, Hong Zheng, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 7793.

https://doi.org/10.1182/blood-2025-7793

Published: 2025

Journal Articles

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Xi Yang, chenglong Li, Hong Zheng, qian Wang, hang Zhang, Xiaobing Huang

Blood (2025) 146 (Supplement 1): 2507.

https://doi.org/10.1182/blood-2025-2507

Published: 2025

Journal Articles

Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study

Boyue Zheng, Jiyi Fu, Jun Wang, Jiafei Wu, Xi Yang, Xiaobing Huang, Hong Zheng, Li Hui

Blood (2025) 146 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2025-3463

Published: 2025

Journal Articles

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

XI Yang, Henry Dumke, Joseph Schroers-Martin, Yazeed Sawalha, Sree Lanka, Izel Okcu, Grzegorz Nowakowski, Peter Doukas, Reem Karmali, Meryl Colton, Michael Spinner, Vincenzo Pizzuti, Manali Kamdar, Olutobi Adewale, Yun Kyoung Tiger, Kelsey Baron, Allison Bock, Marcus Geer, Yasmin Karimi

Blood (2025) 146 (Supplement 1): 783.

https://doi.org/10.1182/blood-2025-783

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Iman Ahmed, Victoria Nachar, Lydia Benitez, Shannon A. Carty, Dahlia Sano, Ryan A. Wilcox, XI Yang, Jonathan Weiss, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2024-205406

Published: 2024

Journal Articles

Targeted Sequencing in Rosai-Dorfman Disease from Microdissected Specimens Reveals Higher Incidence of MAP2K1 Mutations

Andrew L Valesano, Samuel B Reynolds, Sabrina R Wilcox, XI Yang, Haadi Ali, Asra Z. Ahmed, Noah Brown

Blood (2024) 144 (Supplement 1): 6560.

https://doi.org/10.1182/blood-2024-209478

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Efficacy and Safety of Dose-Tailored Mitoxantrone Liposomes Combined with Cytarabine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (Non-M3) Based on Marrow Leukemic Cellularity

Li Hui, FU JIyi, Boyue Zheng, Lianjie HU, Yaqiong LI, Xin WANG, Qing HU, Li Wei, Hai Yi, Ying Yuan, Wang Huan, Yang Haiqing, Xi Yang, Hong Zheng, Yongqian Jia

Blood (2024) 144 (Supplement 1): 6068.

https://doi.org/10.1182/blood-2024-203401

Published: 2024

Journal Articles

Exploring Prognostic Factors of Venetoclax Combined with Azacitidine in Unfit AML Based on Real-World Data from a Chinese Population

Boyue Zheng, FU JIyi, Jiafei Wu, Wang Yu, Jun Wang, Chuanyan Jiang, Wang Huan, Yang Haiqing, Xi Yang, Hong Zheng, Li Hui

Blood (2024) 144 (Supplement 1): 5948.

https://doi.org/10.1182/blood-2024-205623

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma

Real-world efficacy and prognostic modeling of venetoclax-enhanced intensive chemotherapy in fit AML

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia post allogeneic hematopoietic stem cell transplantation.

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients

The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS).

Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Targeted Sequencing in Rosai-Dorfman Disease from Microdissected Specimens Reveals Higher Incidence of MAP2K1 Mutations

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Efficacy and Safety of Dose-Tailored Mitoxantrone Liposomes Combined with Cytarabine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (Non-M3) Based on Marrow Leukemic Cellularity

Exploring Prognostic Factors of Venetoclax Combined with Azacitidine in Unfit AML Based on Real-World Data from a Chinese Population

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only